Tag: SMAD2/3 signaling
-
How Isembyld Releases the Muscle-Growth Brake in Spinal Muscular Atrophy
SMA begins with SMN deficiency and motor-neuron loss, but muscle weakness can persist after SMN-directed treatment. Isembyld targets this downstream component by preventing myostatin activation.